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ABSTRACT
The performance of nucleic acid ampliﬁcation
techniques for detecting respiratory syncytial
virus (RSV) was evaluated in 25 laboratories
across Europe by an external quality assessment
study. In addition, factors related to the diag-
nostic performance of laboratories were
explored. The results of this quality control
study show that the performance of laboratories
for RSV diagnosis in Europe is good, with an
overall correct score of 88%. The type of assay
(nested or real-time PCR vs. commercial tests)
was identiﬁed as a signiﬁcant factor (OR 8.39;
95% CI 1.91–36.78) in predicting a correct
result.
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Respiratory syncytial virus (RSV) is a major cause
of lower respiratory tract infections, particularly
in infants and the elderly [1–3], and leads to
hospitalization and excess mortality [4]. Nucleic
acid ampliﬁcation techniques used for the detec-
tion of RSV can be validated by external quality
assessment studies [5,6]. The aim of this study
was to assess the laboratory performance of RSV
nucleic acid ampliﬁcation techniques and
to identify laboratory-related factors that may
be used to improve the quality of molecular
diagnostic methods for RSV.
Panels with samples were distributed on dry ice
by courier service to 33 laboratories (in 23 Euro-
pean countries) in June 2006 by the QCMDNeutral
Ofﬁce in Glasgow, UK. The panel consisted of nine
coded samples containing RSV-A and ⁄ or RSV-B
(ATCC strain RSV-A-2; ATCC strain RSV-B ⁄WV ⁄
14617 ⁄ 1985wild type) and one sample negative for
RSV. Semiquantitative information was available
in the form of sample dilutions. The sample
preparation procedure guaranteed uniformity
and reproducibility of the panel members. To
ensure conﬁdentiality, all participating laborato-
ries received a code number.
Information on the type of assay (commercial
test, single PCR, nested PCR, real-time PCR),
number of RSV tests performed per year (<500
and ‡500) and the accreditation of the laboratory
was collected in a QCMD questionnaire. An
additional questionnaire included information
on the date of receipt of the panel (no delay,
‡1 week delay), the target gene, whether the
sample was tested for inhibition of the ampliﬁca-
tion reaction, whether the participating laboratory
was a national reference laboratory for RSV, the
European region (east, west), and the training
level of the laboratory staff (no training, personnel
without training or doctoral students; training,
personnel with general training and experienced
personnel; PCR training, personnel with speciﬁc
training for performing PCR). It was hypothe-
sized that these factors could be determinants of
the performance score, and they were therefore
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included in an exploratory analysis to determine
whether they were indeed related to the perfor-
mance of the laboratories.
A sum score was deﬁned (i.e. the number of
correct results; range 0–10) and used to analyse
the performance of the laboratories. Multilevel
logistic regression was used [7] (MLwiN) to
determine which laboratory characteristics were
the best predictors of a correct result. For the
dependent variable (sample score: incorrect = 0;
correct = 1), a logistic regression model was
calculated with the following laboratory charac-
teristics as independent variables: type of assay
(two dummy variables (real-time PCR or nested
PCR and single PCR); reference category ‘com-
mercial assay’), level of training (two dummy
variables; reference category ‘no training’) and
number of RSV tests (<500 or ‡500). The real-time
and nested PCR were combined in the multilevel
analysis, as they were similarly efﬁcient. The data
were analysed at the sample level, with ten
samples for each laboratory for which all data
were available in the questionnaires (n = 18).
The number of participating laboratories was
25 (response rate 76%) from 18 countries, with 20
laboratories from western Europe and ﬁve from
eastern Europe. The overall mean percentage of
correct results was 88%, and ranged from 50% to
100%. The percentage of correct results decreased
in correspondence with the decreasing sample
concentration (Table 1), and RSV-B was less often
correctly detected than RSV-A by a number of
laboratories. One false-positive test result (4%)
was reported for the negative panel sample. The
rate of false-negative results was 14%. The lowest
correct performance scores (60% and 72%) at the
sample level were observed for samples contain-
ing RSV-B only.
The laboratory performance score and its
relation to laboratory characteristics is presented
in Table 2. Statistically signiﬁcant differences in
means were observed for the type of assay
(commercial, single PCR, nested PCR, and real-
time PCR: p 0.026). These results suggest that
there is a difference in performance scores across
the different types of assay, with the highest
performance scores coming from laboratories
using real-time PCR and nested PCR. Most
laboratories used the nucleoprotein gene as
target (n = 12) for the PCR, or this gene in
combination with the phosphoprotein gene
(n = 3) or the surface glycoprotein gene (n = 1).
Other PCR targets were the fusion protein (n = 5),
surface glycoprotein (n = 1) and polymerase
Table 1. Performance score and type of assay according to laboratory
Randomized
laboratory code
Score by sample type and target dilution Score total Type of assay
RSV-A
1.0 · 10)5
(n = 2)
RSV-A
2.0 · 10)6
(n = 2)
RSV-A
1.0 · 10)6
(n = 1)
RSV-B
2.0 · 10)5
(n = 2)
RSV-A/B
2.0 · 10)5/2.0 · 10)4
(n = 2)
RSV-negative
(n = 1)
% correct
score
2 2 2 1 2 2 1 100 In-house Real-time PCR
4 2 2 1 2 2 1 100 In-house Real-time PCR
10 2 2 1 2 2 1 100 In-house Real-time PCR
15 2 2 1 2 2 1 100 In-house Real-time PCR
16 2 2 1 2 2 1 100 In-house Real-time PCR
29 2 2 1 2 2 1 100 In-house Real-time PCR
7 2 2 1 2 2 1 100 In-house Nested PCR
12 2 2 1 2 2 1 100 In-house Nested PCR
28 2 2 1 2 2 1 100 In-house Nested PCR
32 2 2 1 2 2 1 100 In-house Nested PCR
6 2 2 1 2 2 1 100 In-house Multiplex nested PCR
5 2 2 0 2 2 1 90 In-house Real-time PCR
27 2 2 0 2 2 1 90 In-house Real-time PCR
3 2 2 1 1 2 1 90 In-house Nested PCR
1 2 2 0 2 2 1 90 In-house Semi-nested PCR
11 2 2 1 1 2 1 90 In-house Two-step RT-PCR
20 2 2 1 0 2 1 80 In-house Single PCR
31 2 1 1 1 2 1 80 In-house Real-time PCR
13 2 2 1 0 2 1 80 In-house Nested with RT second round
22 2 2 1 0 2 1 80 Commercial Arrow diagnostic
fast set RSV-A ⁄B
26 2 0 0 2 2 1 70 In-house Real-time PCR
9 2 1 1 0 2 1 70 In-house Nested PCR
21 2 2 1 0 2 0 70 In-house Single PCR
18 2 1 0 0 2 1 60 Commercial Euroclone RSV-check kit
33 2 0 0 0 2 1 50 Commercial Finnzymes RobusT II RT-PCR Kit
RSV, respiratory syncytial virus.
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(n = 1) genes. One laboratory used the non-
structural protein-1 gene for RSV-B detection.
The performances of laboratories that used two
target genes (n = 4) did not differ signiﬁcantly
(p 0.076) from those that used one target gene
(n = 19).
To study the effect of each of the relevant
variables corrected by other variables on the
performance score, multilevel logistic regression
analysis was performed. The type of assay, level
of training and the number of swabs tested were
included in the model. The results showed an OR
of 8.39 (95% CI 1.91–36.78) for the in-house PCR
(nested or real-time PCR) vs. commercial PCR,
indicating that the in-house PCRs perform better
than the commercial PCRs.
The different types of assay were also
assessed separately and compared using a con-
trast test for ﬁxed effects in MLwiN, resulting in
a chi-square test statistic. Signiﬁcant differences
in performance scores between commercial and
nested PCR (v2 = 12.92; p <0.001) and between
commercial and real-time PCR (v2 = 14.62; p <
0.001) were observed. Additionally, signiﬁcant
differences were observed between single PCR
and nested PCR (v2 = 3.86; 0.02 < p < 0.05) and
between single PCR and real-time PCR
(v2 = 4.82; 0.02 < p < 0.05). The type of method
was a signiﬁcant factor in predicting a correct
result.
Limitations of the study were the number of
non-respondents (24%) and of incomplete ques-
tionnaires (28%).
Additionally, no clinical isolates were used
and, therefore, only the technical performance
could be determined. Although the absolute
virus quantity in the samples was unknown, it
was possible to use the dilution factors as a
semiquantitative measure. Finally, it may be
possible that the primers of the molecular assays
matched well with the ATCC strains of the
panel, but whether this is also true for the
circulating viruses that are actually present in
clinical samples could not be assessed in this
study.
In conclusion:
(1) with an overall correct score of 88%, the
laboratories involved in the study are
considered to be performing well in the
diagnosis of RSV infection; and
(2) the type of assay applied was the only
signiﬁcant factor in predicting a correct
result, with real-time and nested PCR
performing better than conventional sin-
gle-step and commercial PCR.
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ABSTRACT
The recent description of chronic hepatitis E in
organ transplant recipients deserves increased
awareness in the context of hepatitis E virus
(HEV) infection in immunocompromised individ-
uals. Reported here is what is apparently the ﬁrst
PCR-documented case of acute hepatitis E in a
human immunodeﬁciency virus (HIV)-1-infected
patient. The CD4+ T-lymphocyte count was
246 ⁄mm3. The IgM anti-HEV antibody and HEV
RNA tests results from serum were positive.
Hepatitis was benign, and chronic HEV infection
was ruled out. The HEV genotype was 3f. The
patient did not report recent travel abroad. HEV
should be tested in HIV-infected individuals
presenting with acute hepatitis. HEV RNA detec-
tion is useful in diagnosing HEV infection and in
monitoring recovery.
Keywords Acute hepatitis, autochthonous hepatitis E,
hepatitis E virus, HIV infection, immunosuppression
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